Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
Incyte (
NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable’s enFuse® On-Body Delivery System.
